In women, the difference in SBP between ACE inhibitor users and NoBPMed was significantly greater in those with obesity and overweight compared to normal weight (obesity versus normal weight: −14 ± 1 mmHg versus −9 ± 1 mmHg, P=0.0004; overweight versus normal weight: −14 ± 1 mmHg versus −9 ± 1 mmHg, P=0.001). Here, ACE is linked to obesity due to melanocortin 4 receptor deficiency.